New investigations into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are revealing promising results in managing obesity and type 2 condition. Animal evidence suggest a novel mechanism contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/